Angiotensin II receptor blockers and cardiovascular outcomes: What does the future hold?

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 4, Issue 2, 2003, Pages 62-73

  Weber, Michael A ^a  

^a SUNY Downstate Medical Center   (United States)

Author keywords

ACE inhibitor; Angiotensin II receptor blocker; Cardiovascular protection; Outcome trials; Renin angiotensin aldosterone system

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; IRBESARTAN; LOSARTAN; METOPROLOL; NATEGLINIDE; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; LONG TERM CARE; META ANALYSIS; MORBIDITY; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT;

EID: 0038827402     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2003.015     Document Type: Review

References (70)

1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-71.
2. Bonner G. The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors. Drugs 1997;54:23-30.
3. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy.A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.
4. Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000;2:258-62.
5. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996;51:820-45.
6. McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998;56:847-69.
7. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54:299-311.
8. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001;61:1501-29.
9. McClellan KJ, Balfour JA. Eprosartan. Drugs 1998; 55:713-20.
10. Gardner SF, Franks AM. Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann Pharmacother 2003;37:99-105.
11. Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997;54:885-902.
12. Grossman E, Messerli FH, Neutel JM. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch Intern Med 2000;160:1905-11.
13. Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998;32:1060-6.
14. Dahlöf B, Devereux R, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. Am J Hypertens 1997;10:705-13.
15. Hansson L, Lithell H, Skoog I et al. Study on Cognition and Prognosis in the Elderly (SCOPE): baseline characteristics. Blood Press 2000;9:146-51.
16. Hansson L, Lithell H, Skoog I et al. Study on Cognition and Prognosis in the Elderly (SCOPE). Blood Press 1999;8:177-83.
17. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7:176-83.
18. Pitt B, Chang P, Timmermans PBMWM. Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovasc Drugs Ther 1995;9:693-700.
19. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-52.
20. Pitt B, Poole-Wilson P, Segal R et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study - ELITE II. J Card Fail 1999;5:146-54.
21. Pitt B, Poole-Wilson P, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
22. Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999;5:155-60.
23. Cohn JN, Tognoni G, Glazer R, Spormann D, for the Val-HeFT Investigators. Baseline demographics of the Valsartan Heart Failure Trial. Eur J Heart Fail 2000;2:439-46.
24. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-75.
25. Tsuyuki RT, Yusuf S, Rouleau JL et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997;13:1166-74.
26. Swedberg K, Pfeffer M, Granger C et al. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999;5:276-82.
27. Brenner BM, Cooper ME, de Zeeuw D et al. The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). JRAAS 2000; 1:328-35.
28. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
29. Parving HH, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-8.
30. Rodby RA, Rohde RD, Clarke WR et al.The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrol Dial Transplant 2000;15:487-97.
31. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
32. Toto R. Angiotensin II subtype receptor blockers and renal function. Arch Intern Med 2001;161:1492-9.
33. Rippin J, Bain SC, Barnett AH. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. J Diabetes Complications 2002;16:195-200.
34. Dickstein K, Kjekshus J, for the OPTIMAAL Study Group. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Am J Cardiol 1999;83:477-81.
35. Pfeffer MA, McMurray J, Leizorovicz A et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.
36. Pfeffer MA. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers. Am Heart J 2000;139(1 Pt 2):S23-S28.
37. Yusuf S. From HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002;89:18A-25A.
38. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens 1991;9(suppl 2):S3-S8.
39. Carson P, Giles T, Higginbotham M, Hollenberg N, Kannel W, Siragy HM. Angiotensin receptor blockers: evidence for preserving target organs. Clin Cardiol 2001;24:183-90.
40. Dahlöf B, Devereux RB, Julius S et al. Characteristics of 9194 patients with left ventricular hypertrophy.The LIFE study. Hypertension 1998;32:989-97.
41. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
42. Polidori MC, Marvardi M, Cherubini A, Senin U, Mecocci P. Heart disease and vascular risk factors in the cognitively impaired elderly: implications for Alzheimer's dementia. Aging (Milano) 2001;13:231-9.
43. Birkenhager WH, Forette F, Seux ML, Wang JG, Staessen JA. Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med 2001;161:152-6.
44. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993;15:967-78.
45. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
46. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
47. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
48. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999; 100:1056-64.
49. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
50. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-62.
51. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.
52. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
53. Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. Diabetologia 1996;39:1646-54.
54. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with noninsulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
55. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996;12:127-37.
56. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
57. Dagenais GR, Yusuf S, Bourassa MG et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001; 104:522-6.
58. Unger T, Chung O, Csikos T et al. Angiotensin receptors. J Hypertens 1996;14(suppl 5):S95-S103.
59. de Gasparo M, Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Toxicol 1998;82:257-71.
60. Wienen W, Hauel N, van Meel JC, Narr B, Ries U, Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993;110:245-52.
61. Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998;15:206-17.
62. Lacourcière Y, Lenis J, Orchard R et al.A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998;3:295-302.
63. Karlberg BE, Lins L-E, Hermansson K, for the TEES Study Group. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999;17:293-302.
64. Mallion JM, Sichè JP, Lacourcière Y, the Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999;13: 657-64.
65. Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF.A prospective, randomized, open-label trial comparing telmisartan 80 mg and valsartan 80 mg in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000;16:1123-32.
66. Neutel JM, Kolloch RE, Plouin PF. Comparison of telmisartan monotherapy with losartan + HCTZ in mild-to-moderate hypertension. Am J Hypertens 2000;13:58A-9A [abstract].
67. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001;6:63-72.
68. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998;15:229-40.
69. Lacourcière Y, the Telmisartan Cough Study Group. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Int J Clin Pract 1999;53:99-103.
70. Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83.